 | |
| Type | Subsidiary |
|---|---|
| Industry | Animal healthcare |
| Founded |
|
| Headquarters | Ingelheim, Germany |
| Revenue | €4 billion (2019) [2] |
Number of employees | 10,000 |
| Parent | Boehringer Ingelheim |
| Website | Official website |
Boehringer Ingelheim Animal Health is a multinational animal health company, formed in January 2017 when Merial was acquired by Boehringer Ingelheim and merged with Boehringer Ingelheim's existing animal health assets. [3]
In August 1997, Merial started as a joint venture between the animal health subsidiaries of Merck & Co. (MSD AgVet) and Sanofi-Aventis (Rhône-Mérieux). Merial became the animal health division of Sanofi, when Sanofi bought out Merck's 50% share of the joint venture. On December 30, 2016 Boehringer Ingelheim completed a swap of their OTC business for Sanofi's animal health business. Merial is now owned by Boehringer Ingelheim and combined with their animal health business, Boehringer Ingelheim Vetmedica, to form Boehringer Ingelheim Animal Health.
Merial produces many products and vaccines for domestic pets, farm animals and wildlife. Merial has about 6,900 employees and is present in more than 150 countries in the world. [4] Their sales in 2015 were about €2.5 billion. [5] Some of Merial's most popular products are Frontline, Heartgard, NexGard, Ivomec, PureVax and Previcox.
In October 2009, Merial announced it was investing 70 million US$ at its poultry vaccines plant in Nanchang Hi-tech Development Zone, China. On March 9, 2010, Sanofi-Aventis announced [6] it had exercised an option to combine Merial with Intervet/Schering Plough, the animal health business of Merck. The new joint venture would be equally owned by Merck and Sanofi-Aventis. On March 22, 2011, they announced the mutual termination of their agreement to form a new animal health joint venture.
Boehringer Ingelheim Animal Health's global headquarters is located in Ingelheim, Germany.
Merial was investigated in connection with a 2007 United Kingdom foot-and-mouth outbreak, after a strain of foot-and-mouth disease alleged to have been sourced from one of their research facilities was found at Pirbright, a farm in Surrey, England, in August 2007. [7] The investigators concluded that "release was most likely due to escape of live virus from the drainage system that connects the vaccine production plant to the sodium hydroxide treatment tanks on another part of the Pirbright site." [8]
The two independent inquiries found that Merial complied with all regulations and committed no breaches of biosecurity.
In 2016, the NOAH Code of Practice Committee found Merial Animal Health to be in breach of 2 out of 4 items under complaint. This related to the promotion of NexGard Spectra® to the veterinary profession by both account managers and technical teams via telephone conversations and webinars from February 2016 onwards. [9]
Schering-Plough Corporation was an American pharmaceutical company. It was originally the U.S. subsidiary of the German company Schering AG, which was founded in 1851 by Ernst Christian Friedrich Schering. As a result of nationalization, it became an independent company. In 1971, the Schering Corporation merged with Plough, Inc. to form Schering-Plough. On November 4, 2009 Merck & Co. merged with Schering-Plough with the new company taking the name of Merck & Co.
The Pirbright Institute is a research institute in Surrey, England, dedicated to the study of infectious diseases of farm animals. It forms part of the UK government's Biotechnology and Biological Sciences Research Council (BBSRC). The institute employs scientists, vets, PhD students and operations staff.
Judith Carol Lewent is a business executive who served as chief financial officer of Merck & Co. from 1990 until her retirement from the company in 2007. Since her retirement from Merck, she has continued to serve on multiple corporate boards, including the boards of GlaxoSmithKline, Thermo Fisher Scientific and Motorola Solutions. She also served on the board of Purdue Pharma until her departure from the company in 2014.
C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.
Mumps vaccines are vaccines which prevent mumps. When given to a majority of the population they decrease complications at the population level. Effectiveness when 90% of a population is vaccinated is estimated at 85%. Two doses are required for long term prevention. The initial dose is recommended between 12 and 18 months of age. The second dose is then typically given between two years and six years of age. Usage after exposure in those not already immune may be useful.
The 2007 United Kingdom foot-and-mouth outbreak occurred when the discharge of infectious effluent from a laboratory in Surrey led to foot-and-mouth disease (FMD) infections at four nearby farms. The infections were detected via regular livestock testing by the Department for Environment, Food and Rural Affairs (Defra).
The rabies vaccine is a vaccine used to prevent rabies. There are several rabies vaccines available that are both safe and effective. Vaccinations must be administered prior to rabies virus exposure or within the latent period after exposure to prevent the disease. Transmission of rabies virus to humans typically occurs through a bite or scratch from an infectious animal, but exposure can occur through indirect contact with the saliva from an infectious individual.
Foot-and-mouth disease (FMD) or hoof-and-mouth disease (HMD) is an infectious and sometimes fatal viral disease that affects cloven-hoofed animals, including domestic and wild bovids. The virus causes a high fever lasting two to six days, followed by blisters inside the mouth and near the hoof that may rupture and cause lameness.
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
Olivier Brandicourt is a French business executive and physician, and the former chief executive officer of Sanofi.
Ostertagia ostertagi, commonly known as the medium stomach worm or brown stomach worm, is a parasitic nematode of cattle. O. ostertagi can also be found to a lesser extent in sheep, goats, wild ruminants, and horses. It causes ostertagiosis, which is potentially fatal in cattle. It is found worldwide and is economically important to cattle industries, particularly those found in temperate climates.
Afoxolaner (INN) is an insecticide and acaricide that belongs to the isoxazoline chemical compound group.
Ceva Santé Animale (Ceva) is a multinational animal health company based in Libourne, France. Established in 1999, Ceva undertakes research, development, production and marketing of pharmaceutical products and vaccines, and also provides complementary services and equipment, for companion animals, poultry, ruminants and swine.
